Interpace Biosciences, Inc. (IDXG) stock
IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –
Interpace Biosciences operating margin
Operating margin is operating income as a percentage of revenue.
Interpace Biosciences's operating margin for the twelve months ending Jun 30, 2026 was 11.5%. For fiscal 2025 it was 10.5%, against 17.3% the year before. The highest annual figure on record is 17.3% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10.5% | −6.7 |
| FY2024 | Dec 31, 2024 | 17.3% | +7.4 |
| FY2023 | Dec 31, 2023 | 9.9% | +21.2 |
| FY2022 | Dec 31, 2022 | -11.4% | +65.9 |
| FY2021 | Dec 31, 2021 | -77.3% | +3.2 |
| FY2020 | Dec 31, 2020 | -80.5% | +28.7 |
| FY2019 | Dec 31, 2019 | -109.1% | −51.5 |
| FY2018 | Dec 31, 2018 | -57.7% | −18.1 |
| FY2017 | Dec 31, 2017 | -39.6% | +9.6 |
| FY2016 | Dec 31, 2016 | -49.2% | +379.2 |
| FY2015 | Dec 31, 2015 | -428.4% | +780.9 |
| FY2014 | Dec 31, 2014 | -1209.4% | −1208.4 |
| FY2013 | Dec 31, 2013 | -1.0% | +18.9 |
| FY2012 | Dec 31, 2012 | -19.9% | −16.9 |
| FY2011 | Dec 31, 2011 | -3.0% | +2.1 |
| FY2010 | Dec 31, 2010 | -5.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 3.5% | +8.6 |
| Q1 FY2026 | Mar 31, 2026 | 12.4% | −3.5 |
| Q4 FY2025 | Dec 31, 2025 | 17.1% | +0.5 |
| Q3 FY2025 | Sep 30, 2025 | 13.1% | −5.6 |
| Q2 FY2025 | Jun 30, 2025 | -5.1% | −26.9 |
| Q1 FY2025 | Mar 31, 2025 | 15.9% | +4.9 |
| Q4 FY2024 | Dec 31, 2024 | 16.6% | +1.9 |
| Q3 FY2024 | Sep 30, 2024 | 18.7% | +14.2 |
| Q2 FY2024 | Jun 30, 2024 | 21.9% | +10.8 |
| Q1 FY2024 | Mar 31, 2024 | 10.9% | +2.3 |
| Q4 FY2023 | Dec 31, 2023 | 14.7% | +14.5 |
| Q3 FY2023 | Sep 30, 2023 | 4.5% | +66.0 |
| Q2 FY2023 | Jun 30, 2023 | 11.0% | +108.9 |
| Q1 FY2023 | Mar 31, 2023 | 8.7% | +48.5 |
| Q4 FY2022 | Dec 31, 2022 | 0.2% | +8.0 |
| Q3 FY2022 | Sep 30, 2022 | -61.6% | −38.9 |
| Q2 FY2022 | Jun 30, 2022 | -97.9% | −71.8 |
| Q1 FY2022 | Mar 31, 2022 | -39.8% | −1.0 |
| Q4 FY2021 | Dec 31, 2021 | -7.8% | +74.5 |
| Q3 FY2021 | Sep 30, 2021 | -22.7% | +50.2 |
| Q2 FY2021 | Jun 30, 2021 | -26.1% | +79.9 |
| Q1 FY2021 | Mar 31, 2021 | -38.8% | +31.3 |
| Q4 FY2020 | Dec 31, 2020 | -82.3% | +173.3 |
| Q3 FY2020 | Sep 30, 2020 | -72.8% | +19.5 |
| Q2 FY2020 | Jun 30, 2020 | -106.0% | −20.7 |
| Q1 FY2020 | Mar 31, 2020 | -70.1% | −17.2 |
| Q4 FY2019 | Dec 31, 2019 | -255.6% | −169.5 |
| Q3 FY2019 | Sep 30, 2019 | -92.3% | −49.5 |
| Q2 FY2019 | Jun 30, 2019 | -85.3% | −50.8 |
| Q1 FY2019 | Mar 31, 2019 | -53.0% | +14.6 |
| Q4 FY2018 | Dec 31, 2018 | -86.1% | −10.6 |
| Q3 FY2018 | Sep 30, 2018 | -42.8% | +30.8 |
| Q2 FY2018 | Jun 30, 2018 | -34.5% | +58.8 |
| Q1 FY2018 | Mar 31, 2018 | -67.5% | −174.1 |
| Q4 FY2017 | Dec 31, 2017 | -75.5% | −291.3 |
| Q3 FY2017 | Sep 30, 2017 | -73.7% | +122.0 |
| Q2 FY2017 | Jun 30, 2017 | -93.3% | – |
| Q1 FY2017 | Mar 31, 2017 | 106.6% | – |
| Q4 FY2016 | Dec 31, 2016 | 215.9% | – |
| Q3 FY2016 | Sep 30, 2016 | -195.7% | – |
See a number that looks wrong?